The Life Sciences and AI teams advised insitro in a new collaboration with Eli Lilly and Company (Lilly) to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.
By combining insitro’s advanced computational expertise with Lilly’s extensive drug discovery data, the collaboration seeks to achieve a longstanding industry goal in order to save time and reduce experimentation cycles. The new models could be a game changer for drug researchers, and will be available to insitro, Lilly as well as their own partners, including through Lilly’s new initiative, TuneLab™, which aims to accelerate the development of new medicines by providing biotechs access to powerful machine learning models.
insitro is known as a pioneer in the machine learning-enabled drug discovery and development sector since its founding in 2018. insitro is uncovering genetic targets and new therapeutic hypotheses by integrating multimodal data from human cohorts and cellular models with the power of AI and machine learning to increase the therapeutic probability of success. These insights provide the starting point for discovering new molecules, which are either built with in-house, AI-enabled drug discovery platforms or with partners that extend insitro’s impact. With more than $700 million in capital raised to date, insitro is building a “pipeline through platform” with a focus on metabolic disease and neuroscience. Approaching the clinic, insitro aims to deploy its AI models to run smaller, better powered trials, enrolling the patients who can benefit most.
The Goodwin team was led by Erini Svokos, Beth Withers and Chris Zhong.
For more information about the deal, please read the press release.